Protein tyrosine kinase inhibitors/mTOR-protein inhibitors: Proteinuria: 24 case reports.

Six of the 24 patients developed grade 0-3 proteinuria related to the third-line treatment with everolimus (n=3; total dosage ranging from 140-620mg and treatment duration ranging from 2.1-3.2 months), pazopanib (n=2; total dosage ranging from 20 5800-38 4600mg and treatment duration ranging from 12.7-15.6 months) and sunitinib (n=1; total dosage 4025mg and treatment duration 7.1 months). Three of the 24 patients developed grade 2-3 proteinuria related to the sixth-line treatment with everolimus (n=1; total dosage 1235mg and treatment duration 9.7 months), axitinib (n=1; total dosage 518mg and treatment duration 5.3 months) and pazopanib (n=1; total dosage 6 4400mg and treatment duration 7.4 months). [Extracted from the article]